
Meet the Faces of Zen: Elanco's Zenrelia™ (ilunocitinib tablets) Helps Allergic Dogs Get Back to Normal
GREENFIELD, Ind., January 30, 2025 /3BL/ - Scratching, rubbing, chewing, licking. All signs of an irritated, itchy dog. With approximately 17 million U.S. dogs suffering from allergic skin disease, including atopic dermatitis, food allergies or flea sensitivity,1,2 these are the sounds too many pet parents and veterinarians hear. Today, Elanco Animal Health Incorporated (NYSE: ELAN), is introducing some of the first allergic dogs who have found zen and gotten back to normal by using Zenrelia. Zenrelia, which was approved by the U.S. Food and Drug Administration (FDA) and launched in September 2024, is a highly effective, convenient and safe once-daily oral JAK inhibitor for control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
'Our research shows that when pet owners see their dog at their worst levels of itch, they're concerned, stressed, frustrated and anxious,3' said Bobby Modi, Executive Vice President, U.S. Pet Health and Global Digital Transformation. 'Pet owners shouldn't allow allergic itch to disrupt zen for them or their pups. Zenrelia is designed to begin working from the very first dose4 and help get dogs back to normal.'5
In fact, a newly published study in a leading peer-reviewed, international journal, Veterinary Dermatology, described the findings of a randomized, clinical trial which compared Zenrelia to the leading JAK inhibitor, Apoquel, in over 300 allergic dogs. The full study findings can be found at: https://doi.org/10.1111/vde.13319.
The Zenrelia label includes a boxed warning related to concurrent vaccine administration based on the results of a vaccine response study. It's important for veterinarians to read the entire package insert, including the Boxed Warning, before prescribing Zenrelia.
Meet Some of the Faces of Zen
According to a survey of pet owners, itchy dog owners are eager to get back to a normal life with their dogs, with 82% agreeing they dream of the day their itchy dog becomes normal again and they understand that effective treatment is part of that solution.2 With Zenrelia now widely available, Zenrelia has expanded beyond the clinical trial to helping dogs across the country—and their pet owners—find zen. These real-world results give hope to millions of pet parents whose pets suffer from itch.
Hunter from Ohio, found his zen with Zenrelia. This eight-year-old Chocolate lab suffered with dermatitis most of his life and as he got older, his symptoms—especially licking at his feet and lower legs got worse. His pet parent, Cristy, a receptionist at a vet clinic, tried everything her veterinarian had recommended to bring Hunter relief. Hunter had an extensive regimen of injections every 3-4 weeks, medicated shampoos and wipes, antihistamines, and during parts of the year when he was worse, he was on steroids. Even with this intensive routine his symptoms were never fully controlled—until Hunter took Zenrelia.
'His back feet were pretty much naked up until his first joint and his front feet would be scabby and scaly from the constant licking,' Cristy said. 'It was really discouraging as his dog mom that I couldn't do anything to help him. He's so much more comfortable since being on Zenrelia. It's such a relief that he has relief.'
According to Cristy, 'It's worth talking to your veterinarian to see if it's something that your dog would benefit from.' Individual results may vary and dogs should be up to date on vaccinations prior to starting Zenrelia.
Trooper, a four-year-old Yorkshire Terrier, from Arizona, first got back to normal levels of itch when he participated in the Zenrelia clinical trial. When the trial concluded, the itch returned. His owner, Robin, was excited to get him back on the treatment now that Zenrelia is widely available.
'Allergies are something he's going to have to suffer with his whole life,' said Trooper's pet parent, Robin. 'Having a solution for his allergies is such a relief. It makes my heart happy that I will be able to afford it and give him the relief he deserves.'
Lisa, pet mom to 9-year-old Yorkshire Terrier-Chihuahua mix Scrappy said she 'tried everything under the sun' to help bring Scrappy relief. Scrappy's itching reached the point he lost a significant amount of fur, he didn't want to play or go on walks and no one was getting a good night's rest. Lisa tried numerous treatment options and felt depleted knowing his itch was never fully controlled, until she tried Zenrelia. After two days on Zenrelia, his itch level improved and after eight weeks on Zenrelia, Lisa is happy and relieved to see Scrappy back to a normal dog. According to Lisa, his hair has re-grown, he's taking long walks and he's a happy boy.
'I was excited to get Trooper, Scrappy and some other patients started on Zenrelia as soon as it was available to order,' said Dr. Tom Lewis, veterinarian and founder of Dermatology for Animals, a group of veterinary dermatology clinics committed to caring for pets with allergies. 'Seeing these dogs get back to normal levels of itch and seeing the bond restored between the dog and pet parents is incredibly rewarding. Pet owners should contact their veterinarian and ask if Zenrelia is right for their dog.'
Buckaroo, an eight-year-old mixed breed from Texas, tried numerous treatment options without relief, including steroids and immunotherapy–until his veterinarian recommended Zenrelia. The photos below show Buckaroo's skin before Zenrelia, after three weeks of treatment, and after eight weeks of treatment. His owner noted, 'he's now the happiest boy in the world and his energy levels have increased dramatically.'
'I've had the opportunity to use Zenrelia in my practice and it's helped several of my patients get back to normal levels of itch,' said Dr. Brittany Lancellotti, a veterinary dermatologist at Veterinary Skin and Ear in Los Angeles, California. 'In the fight against allergic dermatitis, I've found that every dog is different - it's great to have another effective treatment option in my toolbox.'
'I work with dermatologists around the country through the American College of Veterinary Dermatology,' said Dr. Andrew Rosenberg, dermatologist, and director of medical operations at Animal Dermatology Clinic in New York and President of the American College of Veterinary Dermatology (ACVD). 'It' great to have another tool in the toolbox especially for both new and severe cases.'
Veterinarians in the U.S. can learn more and place orders for Zenrelia now at ZenreliaForVets.com.
ABOUT ELANCO
Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders and society as a whole. With 70 years of animal health heritage, we are committed to breaking boundaries and going beyond to help our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ sustainability pillars – all to advance the health of animals, people, the planet and our enterprise. Learn more at www.elanco.com.
INDICATIONS
Zenrelia is a prescription medication used to control itching and inflammation associated with skin allergies for dogs over 12 months of age.
IMPORTANT SAFETY INFORMATION
See package insert including the Boxed Warning. For full prescribing information speak with your veterinarian, call 1 888 545 5973 or visit www.elancolabels.com/us/zenrelia.
WARNING: VACCINE-INDUCED DISEASE AND INADEQUATE IMMUNE RESPONSE TO VACCINES. Based on results of the vaccine response study, dogs receiving Zenrelia are at risk of fatal vaccine-induced disease and inadequate immune response to vaccines. Dogs should not take Zenrelia for a time period before and after vaccination. Discuss your dog's vaccine schedule with your veterinarian. Dogs should be up to date on vaccinations prior to starting Zenrelia. Do not use in dogs less than 12 months old or dogs with a serious infection. Dogs should be monitored for the development of infections because Zenrelia may increase the chances of developing an infection. Neoplastic conditions (benign and malignant) were observed during clinical studies. The most common side effects were vomiting, diarrhea and tiredness. Zenrelia has not been tested in dogs used for breeding, pregnant, or lactating dogs and has not been evaluated in combination with glucocorticoids, cyclosporine, or other immune suppressive drugs.
Zenrelia, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. Apoquel is a trademark of Zoetis Services, LLC. © 2025 Elanco or its affiliates.
1. AVMA Pet Ownership and Demographic Sourcebook 2022.
2. Elanco Animal Health. Data on File.
3. Elanco and FleishmanHillard TRUE Global Intelligence Survey.
4. Elanco Animal Health. Data on File.
5. Elanco Animal Health. Data on File.
Media Contact
Investor Contact
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
IQVIA Holdings (NYSE:IQV) Sees 11% Share Price Rise Over Last Week
IQVIA Holdings experienced a 10% rise in share price over the last week, correlating with its recent developments, notably the dosing of the first patient in the RENEW Phase 2 trial and its strategic alliance with Sarah Cannon Research Institute to optimize oncology trials. These initiatives likely provided a positive sentiment boost, aligning well with the broader market momentum, as indices such as the S&P 500 also reached new highs. The market's anticipation over US-China trade talks and overall strong corporate earnings have supported the upward trend, further enhancing IQV's market performance. We've identified 1 warning sign for IQVIA Holdings that you should be aware of. Uncover 18 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The recent 10% rise in IQVIA Holdings' share price has been influenced by important developments like the dosing in the RENEW Phase 2 trial and a key alliance with Sarah Cannon Research Institute. These initiatives are expected to potentially drive revenue growth, particularly as the strategic alliance optimizes oncology trials. The company's past performance, with total returns of 10.45% over five years, suggests modest growth in investor value. However, compared to the US Life Sciences industry's one-year return of 27% decline, IQVIA's recent rise highlights positive market sentiment. These initiatives, combined with FDA reforms and NVIDIA collaboration, may lower operational costs and have a favorable impact on earnings forecasts. Analysts predict revenue to grow by 5.2% annually over the next three years, which is somewhat cautious compared to the general expectations for the life sciences sector. The recent share price movement to US$146.2 remains below the consensus price target of US$216.31, indicating potential for future appreciation if the projected growth in revenue and earnings materializes. Click here to discover the nuances of IQVIA Holdings with our detailed analytical financial health report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:IQV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
2 Weight Loss Drug Stocks That Are Screaming Buys in June
Novo Nordisk and Eli Lilly have most of the GLP-1 drug market to themselves. Based on current pipelines, this state of affairs could continue. Both stocks are attractively priced at the moment. 10 stocks we like better than Novo Nordisk › Is there a hotter trend in healthcare than weight loss drugs? Probably not. Research from Morgan Stanley suggests that sales of weight loss drugs will soar from an estimated $15 billion last year to as much as $150 billion by 2035. That would be a tenfold increase in just over a decade. Most current medications for weight loss are GLP-1 agonists, which suppress patients' appetites by slowing digestion and making them feel full. Two companies, Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY), currently dominate this area, together accounting for an estimated 97% of the market share. Can they can stay atop this fast-growing industry? Here's what I found -- and why they could both be screaming buys right now in June 2025. Whenever an opportunity exhibits such rapid growth, it will inevitably attract competition. Indeed, numerous companies are currently developing weight loss drugs. However, it's quite a leap to assume that Novo Nordisk, with 62% of the GLP-1 market, and Eli Lilly with another 35%, will easily cede their market share to new products. First and foremost, drug development is a challenging process that undergoes rigorous regulatory testing. Many of the drugs in development today will ultimately fail to reach the market. In April, industry heavyweight Pfizer abandoned development of its oral weight loss drug danuglipron, after it may have caused a liver injury in a patient during a clinical trial. Weight loss drugs that do make it to market must then actually compete with what patients already use. That boils down to more than price: Efficacy, side effects, and prescribers' comfort levels with products all make a difference in how these treatments ultimately sell. The weight loss opportunity is currently in its early innings. The leading drugs -- Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound -- are injected, require refrigeration, and remain expensive for patients. Upcoming drugs will include more convenient oral pills; some could be cheaper to produce, and thus could be sold at lower prices. Naturally, Novo Nordisk and Eli Lilly have remained active in order to stay atop the market. Novo Nordisk could soon have an oral GLP-1 agonist for sale; it has filed an application for approval of an oral version of Wegovy. The company hopes to receive a nod by the end of this year. Additionally, its candidate CagriSema, a potential successor to Wegovy, is working through phase 3 trials. At this rate, CagriSema could arrive sometime next year. Eli Lilly is also very active. Its experimental oral weight loss drug, orforglipron, has performed well in phase 3 studies. It could be the first small-molecule drug to hit the market; small-molecule drugs are easier and cheaper to manufacture. Its next-generation injectable therapy, retatrutide, is innovative in that it targets three separate hormones related to hunger. Retatrutide is also currently in phase 3 studies, and could arrive in 2027 if all goes well. Boehringer Ingelheim's survodutide, an injected therapy that could arrive in 2027, is arguably the only potential near-term competition worth noting. There aren't any other immediate threats to Novo Nordisk and Eli Lilly's dominance. The next hopeful, MariTide from Amgen, only begins phase 3 studies in March; if approved, its estimated market arrival would be in 2028. Barring something unexpected, Novo Nordisk and Eli Lilly appear well positioned to capture much of that explosive growth in the weight loss market over the coming years. The question is, which industry giant will do better? Wall Street is currently placing its money on Eli Lilly, as evidenced by the stock's significant valuation premium. Shares trade at a price-to-earnings (P/E) ratio of 62, versus just 22 for Novo Nordisk. Novo Nordisk's CagriSema has struggled to outperform existing treatments in clinical trials, while Eli Lilly's orforglipron has performed well. However, how patients choose treatments involves several factors, so it's not a sure thing that Eli Lilly will capture all this market share from Novo Nordisk. The best solution? Own both. One way to value them is by their PEG ratios, which weigh the stocks' valuations against the companies' expected growth rates: Novo Nordisk PEG ratio: 1.5 Eli Lilly PEG ratio: 1.9 Both companies are reasonably priced for their expected long-term earnings growth, currently 14% annualized for Novo Nordisk and 32% annualized for Eli Lilly. Of course, that could play out differently, but it's all the more reason to own both stocks. One way or another, these two companies will likely split the upside in the weight loss drug market. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Amgen and Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. 2 Weight Loss Drug Stocks That Are Screaming Buys in June was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
Novo Nordisk Stock Climbs on Report Parvus Asset Taking Stake
June 10 - Novo Nordisk (NYSE:NVO) rose to its highest level in over two months Monday after a media report said hedge fund Parvus Asset Management is quietly building a position in the Danish pharmaceutical group. Shares advanced as much as 3%. Warning! GuruFocus has detected 1 Warning Sign with NVO. Parvus is reportedly aiming to influence the company's upcoming leadership transition. Novo Nordisk said in an email that it has nothing to share on this topic. The report follows last month's news that CEO Lars Fruergaard Jorgensen will step down. His departure comes after the company's stock fell sharply from record highs seen in mid-2023. Novo is under mounting pressure in the weight-loss drug market, where Eli Lilly (NYSE:LLY) has made competitive gains. Analysts have pointed to slowing momentum in Novo's drug pipeline, raising questions about long-term growth. Parvus, known for prior activist campaigns at Ryanair and UniCredit, did not disclose how much of Novo it currently owns. This article first appeared on GuruFocus.